| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | RNF35 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human TRIM40 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TRIM40抗体的3篇文献摘要示例(注：以下内容为模拟生成，实际文献可能需要通过数据库检索确认)：
---
1. **文献名称**: *TRIM40 Acts as a Tumor Suppressor in Gastric Cancer by Inhibiting Cell Proliferation via Ubiquitination*
**作者**: Zhang Y, et al.
**摘要**: 本研究通过免疫组化(使用TRIM40特异性抗体)发现TRIM40在胃癌组织中表达下调，其通过介导关键信号蛋白的泛素化降解抑制肿瘤细胞增殖，提示TRIM40可能作为治疗靶点。
---
2. **文献名称**: *TRIM40 Negatively Regulates RIG-I-Mediated Antiviral Immune Response Through K48-Linked Ubiquitination*
**作者**: Li Q, Wang X, et al.
**摘要**: 文章利用TRIM40抗体进行Western blot及免疫共沉淀实验，证实TRIM40通过K48型泛素化修饰RIG-I，负调控抗病毒天然免疫反应，为病毒感染机制提供新见解。
---
3. **文献名称**: *Development and Validation of a Monoclonal Antibody Targeting TRIM40 for Diagnostic Applications*
**作者**: Chen L, et al.
**摘要**: 本研究报道了一种高特异性抗TRIM40单克隆抗体的开发与验证，通过ELISA和免疫荧光验证其灵敏度及特异性，并成功应用于自身免疫病患者血清中TRIM40的检测。
---
建议通过PubMed或Google Scholar以“TRIM40 antibody”或“TRIM40 function”为关键词检索最新文献，或查阅《Cell Death & Disease》《Nature Immunology》等期刊相关研究。
The TRIM40 antibody is a research tool designed to detect and study TRIM40 (Tripartite Motif-containing protein 40), a member of the TRIM family known for its roles in ubiquitination, innate immunity, and cancer regulation. TRIM40 contains a conserved N-terminal TRIM motif (RING, B-box, and coiled-coil domains) and a C-terminal PRY-SPRY domain, which may mediate protein-protein interactions. Functionally, TRIM40 acts as an E3 ubiquitin ligase, promoting proteasomal degradation of target proteins through ubiquitination. Studies suggest it regulates inflammatory signaling pathways (e.g., NF-κB) and may act as a tumor suppressor in certain cancers by targeting oncoproteins for degradation. For instance, TRIM40 has been reported to be downregulated in hepatocellular carcinoma and colorectal cancer, correlating with poor prognosis.
The antibody is typically generated using recombinant TRIM40 protein or synthetic peptides as immunogens, often in hosts like rabbits or mice. It enables detection of endogenous TRIM40 in applications such as Western blotting, immunofluorescence, and immunoprecipitation. Validation usually includes knockout cell lines or siRNA-mediated silencing to confirm specificity. Researchers use TRIM40 antibodies to explore its expression patterns, subcellular localization (e.g., cytoplasmic or nuclear), and interactions with signaling molecules. Recent interest focuses on its role in autoimmune diseases, viral infection responses, and cancer progression, making it a potential biomarker or therapeutic target. However, variability in antibody performance across experimental conditions necessitates careful optimization.
×
